Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2024-03-07 00:00:00 ET · period of report 2024-03-05 · accession 0000950170-24-028002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-03-07 | 2024-03-05 | TEVA | Drape Eric | Executive VP Gbl Ops | M - OptEx | — | +77.8K | 145.9K | +114% | — |
| DMT | 2024-03-07 | 2024-03-05 | TEVA | Drape Eric | Executive VP Gbl Ops | M - OptEx | $0.00 | -77.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-03-05 | M | A | 22,576 | — | 90,689 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F3) Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. |
| 2 | Common | Ordinary Shares | 2024-03-05 | M | A | 55,226 | — | 145,915 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F3) Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. |
| 3 | Derivative | Restricted Share Units | 2024-03-05 | M | D | 22,576 | $0.00 | 22,576 | D | — · — to — | 22,576 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F4) Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025. |
| 4 | Derivative | Restricted Share Units | 2024-03-05 | M | D | 55,226 | $0.00 | 0 | D | — · — to — | 55,226 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F5) Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. |